Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Non-Current Liabilities: 2022-2025

Historic Total Non-Current Liabilities for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $96.0 million.

  • Taysha Gene Therapies' Total Non-Current Liabilities rose 104.03% to $96.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.0 million, marking a year-over-year increase of 104.03%. This contributed to the annual value of $87.5 million for FY2024, which is 9.03% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Total Non-Current Liabilities stood at $96.0 million for Q3 2025, which was up 15.36% from $83.2 million recorded in Q2 2025.
  • Taysha Gene Therapies' Total Non-Current Liabilities' 5-year high stood at $241.1 million during Q3 2023, with a 5-year trough of $47.0 million in Q3 2024.
  • Its 3-year average for Total Non-Current Liabilities is $97.2 million, with a median of $87.5 million in 2024.
  • Per our database at Business Quant, Taysha Gene Therapies' Total Non-Current Liabilities surged by 150.03% in 2023 and then tumbled by 80.48% in 2024.
  • Taysha Gene Therapies' Total Non-Current Liabilities (Quarterly) stood at $121.2 million in 2022, then fell by 20.61% to $96.2 million in 2023, then declined by 9.03% to $87.5 million in 2024, then spiked by 104.03% to $96.0 million in 2025.
  • Its Total Non-Current Liabilities stands at $96.0 million for Q3 2025, versus $83.2 million for Q2 2025 and $82.1 million for Q1 2025.